---
title: "Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284637615.md"
description: "The trial was assessed by the Independent Data Monitoring Committee (IDMC) and found to be unlikely to achieve the primary endpoint."
datetime: "2026-04-29T20:07:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284637615.md)
  - [en](https://longbridge.com/en/news/284637615.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284637615.md)
generator: "portal-rs"
---

# Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

The trial was assessed by the Independent Data Monitoring Committee (IDMC) and found to be unlikely to achieve the primary endpoint.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [ALEC.US](https://longbridge.com/en/quote/ALEC.US.md)

## Related News & Research

- [Don't Ignore The Insider Selling In Alector](https://longbridge.com/en/news/298133463.md)
- [GSK Reports Executive Acquisition of Notional ADS in Savings Plan](https://longbridge.com/en/news/298612659.md)
- [Alector (NASDAQ:ALEC) Insider Grace Wong-Sarad Sells 5,165 Shares of Stock](https://longbridge.com/en/news/298081109.md)
- [Alector Principal Accounting Officer Grace Wong-Sarad disposes of 9,446 common shares worth $24,060.92](https://longbridge.com/en/news/298078357.md)
- [Alector to present at Cantor Global Healthcare Conference 2026 fireside chat](https://longbridge.com/en/news/297952717.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**